Doxifluridine

Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs[1][2][3].

Product Specifications

CAS Number

[3094-09-5]

Product Name Alternative

Ro 21-9738; 5-Fluoro-5'-deoxyuridine; 5'-DFUR

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Thymidylate Synthase

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Doxifluridine.html

Purity

99.91

Solubility

DMF : 100 mg/mL (ultrasonic) |DMSO : ≥ 100 mg/mL|H2O : 20 mg/mL (ultrasonic)

Smiles

O=C(N1)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=C(F)C1=O

Molecular Formula

C9H11FN2O5

Molecular Weight

246.19

Precautions

H315, H319, H335

References & Citations

[1]Naganuma Y, et al. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci. 2011 Aug;102 (8) :1545-52.|[2] Berne M, et al. Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. Cancer Invest. 1988;6 (4) :377-83. |[3]Di Bartolomeo M, et al. Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study. Tumori. 1999 May-Jun;85 (3) :211-3.